Dr. Cluff, the creator of SLIM TLC®, predicts that, because of this class of medicines, called "GLP-1 (or GLP-1/GIP) RAs (receptor agonists)" (hopefully combined with SLIM TLC®), the 2020s will forever be looked back upon in history as the decade that the rise in the "diabesity" epidemic began to plummet (the far reaching effects of which can now only be imagined) – along with the rate of almost every other metabolic disease. Together, diseases that are primarily metabolic (including heart disease, cancer, stroke, diabetes, and even Alzheimer's disease) represent half of the top ten causes of death, and are responsible for >50% of all deaths. We have the privilege of being grateful eyewitnesses to the unfolding of this phenomenon of disease prevention and/or reversal.

Fortunately, these medicines are FDA-approved for long-term use, so as far as we now know, you never have to stop taking them – even if/after you reach your goal (at which time you should be able to decrease the dose and frequency, thus decreasing costs).

This version of SLIM TLC® combines Wegovy® (semaglutide), a GLP-1 RA (glucagon-like peptide-1 receptor agonist), or Zepbound® (tirzepatide), a GLP-1/GIP (glucose-dependent insulinotropic peptide) RA, with livable Therapeutic Lifestyle Changes (TLCs)